Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Brian Godman, Rickard Malmström, Eduardo Diogène, Andy Gray, Sisira Jayathissa, Angela Timoney, Francisco Acúrcio, Ali Alkan, Anna Brzezinska, Anna Bucsics, Stephen Campbell, Jadwiga Czeczot, Winnie De Bruyn, Irene Eriksson, Faridah Yusof, Alexander Finlayson, Jurij Fürst, Kristina Garuolienè, Augusto Guerra Júnior, Jolanta Gulbinovic & 20 others Saira Jan, Roberta Joppi, Marija Kalaba, Einar Magnisson, Laura McCullagh, Kaisa Miikkulainen, Gabriela Ofierska-Sujkowska, Hanne Bak Pedersen, Gisbert Selke, Catherine Sermet, Susan Spillane, Azuwana Supian, Ilse Truter, Vera Vlahovic-Palcevski, Low Ee Vien, Elif H Vural, Janet Wale, Magdalena Wladysiuk, Wenjie Zeng, Lars L Gustafsson

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

Original languageEnglish
Pages (from-to)77-94
Number of pages18
JournalExpert Review of Clinical Pharmacology
Volume8
Issue number1
Early online dateDec 2014
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Health Expenditures
Rare Diseases
Delivery of Health Care
Drug Evaluation
Health
Financial Management
Pharmaceutical Preparations

Cite this

Godman, B., Malmström, R., Diogène, E., Gray, A., Jayathissa, S., Timoney, A., ... Gustafsson, L. L. (2015). Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Review of Clinical Pharmacology, 8(1), 77-94. https://doi.org/10.1586/17512433.2015.990380
Godman, Brian ; Malmström, Rickard ; Diogène, Eduardo ; Gray, Andy ; Jayathissa, Sisira ; Timoney, Angela ; Acúrcio, Francisco ; Alkan, Ali ; Brzezinska, Anna ; Bucsics, Anna ; Campbell, Stephen ; Czeczot, Jadwiga ; De Bruyn, Winnie ; Eriksson, Irene ; Yusof, Faridah ; Finlayson, Alexander ; Fürst, Jurij ; Garuolienè, Kristina ; Júnior, Augusto Guerra ; Gulbinovic, Jolanta ; Jan, Saira ; Joppi, Roberta ; Kalaba, Marija ; Magnisson, Einar ; McCullagh, Laura ; Miikkulainen, Kaisa ; Ofierska-Sujkowska, Gabriela ; Bak Pedersen, Hanne ; Selke, Gisbert ; Sermet, Catherine ; Spillane, Susan ; Supian, Azuwana ; Truter, Ilse ; Vlahovic-Palcevski, Vera ; Vien, Low Ee ; Vural, Elif H ; Wale, Janet ; Wladysiuk, Magdalena ; Zeng, Wenjie ; Gustafsson, Lars L. / Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. In: Expert Review of Clinical Pharmacology. 2015 ; Vol. 8, No. 1. pp. 77-94.
@article{a5b6c2ad511d47e3a0cc06bec03e9ee9,
title = "Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?",
abstract = "Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.",
keywords = "clinical pharmacology, critical drug evaluation, dabigatran, differential pricing, ivacaftor, managed entry agreements, new models, rational use of medicines, sofosbuvir, trastuzumab emtansine",
author = "Brian Godman and Rickard Malmstr{\"o}m and Eduardo Diog{\`e}ne and Andy Gray and Sisira Jayathissa and Angela Timoney and Francisco Ac{\'u}rcio and Ali Alkan and Anna Brzezinska and Anna Bucsics and Stephen Campbell and Jadwiga Czeczot and {De Bruyn}, Winnie and Irene Eriksson and Faridah Yusof and Alexander Finlayson and Jurij F{\"u}rst and Kristina Garuolien{\`e} and J{\'u}nior, {Augusto Guerra} and Jolanta Gulbinovic and Saira Jan and Roberta Joppi and Marija Kalaba and Einar Magnisson and Laura McCullagh and Kaisa Miikkulainen and Gabriela Ofierska-Sujkowska and {Bak Pedersen}, Hanne and Gisbert Selke and Catherine Sermet and Susan Spillane and Azuwana Supian and Ilse Truter and Vera Vlahovic-Palcevski and Vien, {Low Ee} and Vural, {Elif H} and Janet Wale and Magdalena Wladysiuk and Wenjie Zeng and Gustafsson, {Lars L}",
year = "2015",
doi = "10.1586/17512433.2015.990380",
language = "English",
volume = "8",
pages = "77--94",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

Godman, B, Malmström, R, Diogène, E, Gray, A, Jayathissa, S, Timoney, A, Acúrcio, F, Alkan, A, Brzezinska, A, Bucsics, A, Campbell, S, Czeczot, J, De Bruyn, W, Eriksson, I, Yusof, F, Finlayson, A, Fürst, J, Garuolienè, K, Júnior, AG, Gulbinovic, J, Jan, S, Joppi, R, Kalaba, M, Magnisson, E, McCullagh, L, Miikkulainen, K, Ofierska-Sujkowska, G, Bak Pedersen, H, Selke, G, Sermet, C, Spillane, S, Supian, A, Truter, I, Vlahovic-Palcevski, V, Vien, LE, Vural, EH, Wale, J, Wladysiuk, M, Zeng, W & Gustafsson, LL 2015, 'Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?', Expert Review of Clinical Pharmacology, vol. 8, no. 1, pp. 77-94. https://doi.org/10.1586/17512433.2015.990380

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? / Godman, Brian; Malmström, Rickard; Diogène, Eduardo; Gray, Andy; Jayathissa, Sisira; Timoney, Angela; Acúrcio, Francisco; Alkan, Ali; Brzezinska, Anna; Bucsics, Anna; Campbell, Stephen; Czeczot, Jadwiga; De Bruyn, Winnie; Eriksson, Irene; Yusof, Faridah; Finlayson, Alexander; Fürst, Jurij; Garuolienè, Kristina; Júnior, Augusto Guerra; Gulbinovic, Jolanta; Jan, Saira; Joppi, Roberta; Kalaba, Marija; Magnisson, Einar; McCullagh, Laura; Miikkulainen, Kaisa; Ofierska-Sujkowska, Gabriela; Bak Pedersen, Hanne; Selke, Gisbert; Sermet, Catherine; Spillane, Susan ; Supian, Azuwana; Truter, Ilse; Vlahovic-Palcevski, Vera; Vien, Low Ee; Vural, Elif H; Wale, Janet; Wladysiuk, Magdalena; Zeng, Wenjie; Gustafsson, Lars L.

In: Expert Review of Clinical Pharmacology, Vol. 8, No. 1, 2015, p. 77-94.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

AU - Godman, Brian

AU - Malmström, Rickard

AU - Diogène, Eduardo

AU - Gray, Andy

AU - Jayathissa, Sisira

AU - Timoney, Angela

AU - Acúrcio, Francisco

AU - Alkan, Ali

AU - Brzezinska, Anna

AU - Bucsics, Anna

AU - Campbell, Stephen

AU - Czeczot, Jadwiga

AU - De Bruyn, Winnie

AU - Eriksson, Irene

AU - Yusof, Faridah

AU - Finlayson, Alexander

AU - Fürst, Jurij

AU - Garuolienè, Kristina

AU - Júnior, Augusto Guerra

AU - Gulbinovic, Jolanta

AU - Jan, Saira

AU - Joppi, Roberta

AU - Kalaba, Marija

AU - Magnisson, Einar

AU - McCullagh, Laura

AU - Miikkulainen, Kaisa

AU - Ofierska-Sujkowska, Gabriela

AU - Bak Pedersen, Hanne

AU - Selke, Gisbert

AU - Sermet, Catherine

AU - Spillane, Susan

AU - Supian, Azuwana

AU - Truter, Ilse

AU - Vlahovic-Palcevski, Vera

AU - Vien, Low Ee

AU - Vural, Elif H

AU - Wale, Janet

AU - Wladysiuk, Magdalena

AU - Zeng, Wenjie

AU - Gustafsson, Lars L

PY - 2015

Y1 - 2015

N2 - Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

AB - Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

KW - clinical pharmacology

KW - critical drug evaluation

KW - dabigatran

KW - differential pricing

KW - ivacaftor

KW - managed entry agreements

KW - new models

KW - rational use of medicines

KW - sofosbuvir

KW - trastuzumab emtansine

UR - http://www.scopus.com/inward/record.url?scp=84916931880&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/new-models-needed-optimize-utilization-new-medicines-sustain-healthcare-systems-1

U2 - 10.1586/17512433.2015.990380

DO - 10.1586/17512433.2015.990380

M3 - Article

VL - 8

SP - 77

EP - 94

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 1

ER -